Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction. We evaluated the safety, efficacy and convenience of tobramycin inh...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of cystic fibrosis Vol. 10; no. 1; pp. 54 - 61
Main Authors:	Konstan, Michael W., Flume, Patrick A., Kappler, Matthias, Chiron, Raphaël, Higgins, Mark, Brockhaus, Florian, Zhang, Jie, Angyalosi, Gerhild, He, Ellie, Geller, David E.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.01.2011
Subjects:	Administration, Inhalation Adolescent Adult Aged Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Child Cough - chemically induced Cystic fibrosis Cystic Fibrosis - complications Cystic Fibrosis - physiopathology Drug Administration Schedule Drug Delivery Systems Drug Monitoring Dry Powder Inhalers Female Humans Lung infection Male Middle Aged Powders Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - isolation & purification Pseudomonas Infections - drug therapy Pseudomonas Infections - etiology Pseudomonas Infections - physiopathology Pulmonary/Respiratory Respiratory Function Tests Sputum - drug effects Sputum - microbiology Tobramycin - administration & dosage Tobramycin - adverse effects Tobramycin inhalation powder (TIP™) Treatment Outcome Tobramycin inhalation powder (TIP™) Cystic fibrosis Pseudomonas aeruginosa Lung infection
ISSN:	1569-1993, 1873-5010, 1873-5010
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!